We are pleased to be able to offer you a broad portfolio of Finished Dosage Forms, covering all therapeutic areas and various types of technologies.
At Galenicum Axium, we focus on three different lines of work. On the one hand, more innovative and complex developments based on our know-how acquired throughout the years in different types of pharmaceutical products. On the other hand, the development of products that will become off-patent in the next 10-20 years. And, finally, the improvement of our already existing portfolio.
Contact our team for further information on our portfolio!
PRODUCTS
Available dosages:
1500 mg liquid stick pack
500 mg tablets
Available dosages:
1 mg tablets
Available dosages:
5 & 10 mg tablets
Available dosages:
5/850 & 5/1000mg tablets
Available dosages:
10 & 25 mg tablets
Available dosages:
5/500, 5/850, 5/1000, 12.5/500, 12.5/850 & 12.5/1000mg tablets
Available dosages:
10 & 25 mg tablets
Available dosages:
5mg tablets
Available dosages:
2.5/850 mg & 2.5/1000 mg
Available dosages:
0.6, 1.2 & 1.8mg & 0.6, 1.2, 1.8, 2.4 & 3mg pre-filled cartridge pen
Available dosages:
500, 850 & 1000 mg tablets
Available dosages:
2mg/1.5mL (1.34 mg/mL) pre-filled cartridge pen
Available dosages:
10 mg/mL solution for injection
Available dosages:
25, 50 & 100 mg tablets
Available dosages:
50/1000 mg, 50/850 mg & 50/500 mg tablets
Available dosages:
2.5, 5, 7.5, 10, 12.5 & 15mg/0.5mL pre-filled cartridge pen
Available dosages:
50 mg tablets
Available dosages:
50/850 mg & 50/1000 mg tablets
Available dosages:
10 & 20mg tablets
PRODUCTS
Available dosages:
100 mg tablets
Available dosages:
75, 110 & 150 mg capsules
Available dosages:
12.5, 25, 50 & 75mg + 100mg tablets
PRODUCTS
Available dosages:
150mg/100mL (1.8mg/mL) & 360mg/200mL (1.5mg/mL) infusion bag
Available dosages:
180mg tablets
Available dosages:
5, 10, 20 & 40 mg tablets
Available dosages:
284 mg/1.5mL (189 mg/mL) subcutaneous solution
Available dosages:
10, 20, 30, 40, 60 & 80 mg tablets
PRODUCTS
Available dosages:
0.5 mg/g + 50 mcg/g gel
PRODUCTS
Available dosages:
0.5 mg soft gel capsules
Available dosages:
0.5/0.4 mg capsules
PRODUCTS
Available dosages:
50 & 70 mg injection
Available dosages:
50 & 100 mg injection
Available dosages:
500mg injection
Available dosages:
50 mg injection
Available dosages:
1g & 2g injection
Available dosages:
200mg injection
PRODUCTS
Available dosages:
0.5 & 1 mg capsuless
Available dosages:
1 mg tablets
Available dosages:
7.9mg capsules
Available dosages:
2.5 mg tablets
Available dosages:
25mg soft gel capsules
Available dosages:
EQ 62mg base/vial subcutaneous powder
Available dosages:
5, 10, 15, 20 & 25mg tablets
PRODUCTS
Available dosages:
25 mg oral solution stick pack
12.5 & 25 mg tablets
Available dosages:
25 mg oral solution stick pack
400mg, 600mg tablets
Available dosages:
10, 20 & 30 mg base/vial
Available dosages:
20.4, 0.56 & 1.2mg powder
PRODUCTS
Available dosages:
12.5 mg tablets
Available dosages:
500 mg/5 ml & 1 g/10 ml oral solution stick pack
Available dosages:
10mg/2ml pre-filled syringes
50mg/10ml vials
Available dosages:
30mg/100ml infusion bag
Available dosages:
61mg soft gel capsules
Available dosages:
20mg soft gel capsules
Available dosages:
100mg/ml oral solution 30ml, 60ml & 90ml
500, 650 & 1000mg tablets
Available dosages:
2mg/ml - 120ml oral solution bottle
Available dosages:
20ml lyophilized powder for Injection
PRODUCTS
Available dosages:
1mg/ml - 10ml nasal spray bottle
PRODUCTS
Available dosages:
1mg/ml ophthalmic suspension
PRODUCTS
Available dosages:
40mg/5mL (8mg/mL) intraveneous solution
Available dosages:
50mg/10mL & 10mg/2mL solution for injection
Available dosages:
200mg/2ml & 500mg/5ml injection
RESTRICTED ACCESS
The information contained in this section is aimed at the healthcare professional of the Pharmaceutical Industry, therefore, specialized training is required for its correct interpretation.
The products mentioned may have a different authorized data sheet in each country.
If you click the "accept" button, you are expressing your willingness to access the information explicitly intended for healthcare professionals.
DABIGAMAX
DEVELOPMENT OF THE FIRST GENERIC PHARMACEUTICAL SPECIALTY WITH DABIGATRAN. Decision EMC/2755/2017, dated November 20, (DOGC núm. 7508 of 30/11/2017) regarding the call for NUCLEUS OF INDUSTRIAL RESEARCH AND EXPERIMENTAL DEVELOPMENT (file number RD17-1-0006). This project has received funding from the European Union through the European Regional Development Fund (ERDF). With the collaboration from ACCIÓ.